Purpose of review Glutathione (GSH) is a major endogenous antioxidant. Several studies have implicated GSH redox imbalance in brain disorders. Here, we summarize current evidence on how GSH depletion and GSHrelated enzyme deficit are involved in the pathology of brain disorders such as autism, schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease.
INTRODUCTION
Glutathione (GSH) is the most important endogenous antioxidant and plays an important role in the detoxification of xenobiotics and their metabolites, as well as in the maintenance of the intracellular redox balance [1 && ,2,3]. Redox homeostasis is very important in the brain, where high oxygen consumption produces many harmful free radicals, such as reactive oxygen species (ROS). In addition, GSH has other pivotal functions in the cells, such as modulation of cellular differentiation/proliferation and apoptosis [1 && ,2,3]. GSH is a tripeptide containing glutamate, cysteine, and glycine amino acids. It is distributed ubiquitously, with varying levels throughout the human body. In the brain, GSH concentration is highest in glial cells of the cortex [1 && ]. The pathway of maintaining intracellular GSH homeostasis includes GSH redox cycling, direct uptake, and de-novo synthesis (Fig. 1) . GSH is synthesized in the cytosol through two consecutive ATP-dependent enzymatic reactions catalyzed by glutamate cysteine ligase (GCL) and glutathione synthetase (GS). GCL consisting of a catalytic (heavy) subunit (GCLC) and a modulatory (light) subunit (GCLM) mediates the first step of GSH synthesis, that is, the reaction of glutamate and cysteine to form gglutamylcysteine (gGC). Then, gGC is coupled with glycine to form GSH in a reaction catalyzed by GS. Cysteine is the rate-limiting amino acid for GSH synthesis because its levels are lower than those of glutamate or glycine, and GCL is the rate-limiting enzyme [1 && ,2]. The sulfhydryl group of the cysteine moiety provides the reducing equivalents of the GSH. GSH is oxidized to glutathione disulfide (GSSG) by glutathione peroxidase (GPx) during detoxification of H 2 O 2 or organic hydroperoxide, and GSSG can also be converted back to GSH by glutathione reductase (GR). Glutathione S-transferase (GST) participates in the detoxification of xenobiotic compounds by catalysing their conjugation with GSH to form nontoxic products.
GSH imbalance/depletion has been reported to be involved in many brain disorders such as autism [4,5 & ,6], Alzheimer's disease [7 & 
], bipolar disorder [9] , schizophrenia [10] , amyotrophic lateral sclerosis [11] , Huntington's disease [12] , and multiple sclerosis [13] (Table 1) . GSH deficit may precede the neuropathology of these diseases, and neuronal GSH depletion may be a primary cause of these brain diseases. The purpose of this review is to summarize the critical role of GSH in the brain, particularly in neuropsychiatric and neurodegenerative diseases.
GLUTATHIONE REDOX IMBALANCE IN AUTISM
Autism is a heterogeneous disorder characterized by impairments in social and communicative behaviors, as well as by repetitive and stereotypic patterns of behavior [14] . The prevalence of autism spectrum disorders (ASDs) has increased considerably for the past several decades, and is estimated to be one in 68 children of 8 years of age, according to a report of the Centers for Disease Control and Prevention [15] . The cause and pathological mechanism of autism are still elusive, although genetic and environmental factors, oxidative stress, mitochondrial dysfunction, and immune abnormalities have been suggested to play important roles in the development of autism [16] [17] [18] [19] [20] .
Studies from our and other groups have reported lower levels of GSH, increased levels of GSSG, and decreased ratio of GSH/GSSG in the blood, brain tissues, and lymphoblastoid cells from autistic individuals as compared with controls [6, [21] [22] [23] [24] . These findings indicate the presence of GSH deficit and GSH redox imbalance in individuals with autism [22, 24] . Interestingly, decreased GSH levels and GSH/GSSG redox ratio were brain region-specific and were observed in the cerebellum and temporal cortex of autistic individuals compared with agematched controls [6] . Such alterations in GSH status were not observed in the frontal, parietal, and occipital cortex of the autistic individuals [6] .
Recently, we reported a significant decrease in the activities of GSH-related enzymes, that is, GPx, GST, and GCL in the cerebellum of individuals with autism compared with the control group [5 & ]. GR activity was also reduced in 40% of autistic individuals. The protein levels of GCLM subunits were decreased, and the GCLC/GCLM ratio was
KEY POINTS
Several studies have reported deficit in GSH (a major antioxidant) in many brain disorders such as autism, Alzheimer's disease, Parkinson's disease, and schizophrenia.
The protein expression and/or activities of GSH-related enzymes such as GPx, GR, GST, and GCL are also impaired in the brain disorders.
Agents such as NAC, liposomes encapsulated with GSH, and whey protein supplement that can increase the levels of GSH may be of potential therapeutic value in these brain disorders. significantly increased in the cerebellum from autistic individuals compared with those in the agematched controls [5 & ]. The linear regression analysis displayed a strong positive relationship between the GCL activity and the protein levels of GCLM and GCLC in the controls, but not in autistic individuals. GCLM is enzymatically inactive but plays an important regulatory function by increasing the V (max) and K (cat) of GCLC, by lowering the K (m) of GCL for glutamate and ATP, and by raising the K (i) for GSH-mediated feedback inhibition of GCL [3] . These studies suggest that GSH-related antioxidant and detoxification properties, as well as synthesis of GSH are impaired in the brains of individuals with autism. The lower GCL activity in autism appears to be related to reduced GCLM protein expression and dysregulation of GCL activity. These findings may contribute to understanding of how GSH levels are affected in autism and of how altered GSH homeostasis may be associated with oxidative stress and mitochondrial dysfunction, leading to the development and pathogenesis of autism.
In blood samples from autistic individuals, the alterations of GPx activity and other antioxidant enzymes were not consistent in different research studies [19, 22] . The results of meta-analyses showed that GPx activity was significantly lower in erythrocytes, but not in the serum or platelets, from individuals with ASD than that in controls [19, 22] . Alabdali et al. [25] reported that individuals with ASD had significantly higher levels of toxic heavy metals (lead and mercury) and lower GST activity and vitamin E concentrations in the erythrocytes compared with the controls.
GSH synthesis is related to methylation metabolism through homocysteine and cysteine and to the folate cycle through methionine synthase (MS) [26] . Therefore, the GSH levels are indirectly affected by the methylation and folate metabolism. MS is an enzyme that is highly sensitive to cellular oxidative status. Lower MS activity increases the production of the antioxidant GSH, while decreasing more than 200 methylation reactions. Hodgson et al. [27] reported decreased levels of GSH and elevated levels of homocysteine and S-adenosylhomocysteine (SAH) in serum from autistic individuals, suggesting oxidative stress and decreased MS activity. Furthermore, autistic men had lower GSH and higher Table 1 . Changes of glutathione and glutathione-related enzymes in the blood and brain of individuals with brain disorders
Disease
In the blood In the brain homocysteine levels as compared with women, whereas homocysteinylation of serum proteins was increased in autistic men but not in women [27] . Muratore et al. [28] reported that mRNA levels of MS were significantly lower in the brain of autistic individuals, especially at younger ages. Interestingly, this decrease was replicated in cultured human neuronal cells by treatment with tumor necrosis factor-alpha, whose levels in the cerebrospinal fluid are elevated in autism [28] . In another study, Frye et al. [29] reported that the treatment with methylcobalamin and folinic acid for 3 months significantly improved the GSH redox status and behaviors in expressive communication, personal and domestic daily living skills, and interpersonal, play-leisure, and social skills. GSH synthesis is also related to mitochondrial functions, which produces ATP that is essential for GSH synthesis. On the contrary, lower GSH levels can also lead to mitochondrial dysfunction because of higher levels of ROS. Children with autism/mitochondrial dysfunction demonstrated higher GSH/ GSSG ratios and lower GSSG levels as compared with autistic children without mitochondrial dysfunction, although these two groups had lower GSH levels and GSH/GSSG ratio compared with the control group [30] .
GLUTATHIONE REDOX IMBALANCE IN ALZHEIMER'S DISEASE
Alzheimer's disease is a neurodegenerative disease, which has two pathological hallmarks: neurofibrillary tangles and amyloid plaques in the brain. Several studies have shown GSH redox imbalance during the onset and progression of Alzheimer's disease. Decreased GSH levels have been reported in the blood and brain samples of Alzheimer's disease patients, and there was a correlation between GSH/GSSG ratio and cognitive performance assessed by Mini-Mental Status Examination in patients with Alzheimer's disease [7 & ]. Furthermore, it has also been suggested that GSH content and GSH/GSSG ratio in the blood may be used as the biomarker of onset and progression of Alzheimer's disease [7 & ]. Brain GSH monitoring with magnetic resonance spectroscopy (MRS) is also considered an important tool for the diagnosis of Alzheimer's disease [7 & ]. Zhang et al. [31] reported that the GSH/GSSG ratio decreased before the onset of amyloid plaques, followed by a continual increase in GSSG and a decrease in GSH/GSSG ratio in the brains of a transgenic mouse model of Alzheimer's disease. Mandal et al. [32] , using MRS, analyzed GSH contents in different brain regions of healthy male/female individuals and Alzheimer's disease patients. It was reported that GSH contents in the brain of healthy individuals were associated with the sex and brain region. At the same region of the brain, GSH content was higher in healthy women as compared with healthy men. For the Alzheimer's disease patients, GSH contents reduced significantly in the right frontal cortex of women and in the left frontal cortex of men compared with the matched controls [32] . Recently, Duffy et al. [33] reported that mild cognitive impairment was associated with increased GSH levels in the anterior and posterior cingulate, which in turn related to neuropsychological performance. It is possible that there is an early compensatory or neuroprotective mechanism to counteract the increased oxidative stress that occurs during the onset of Alzheimer's disease.
GSH is also indirectly related to the proteolysis of b amyloid (Ab). Lasierra-Cirujeda et al. [34] suggested that GSH has an important interaction with the plasminogen/plasmin system, which is one of the enzymes that degrade Ab. The depletion of GSH produces inhibition of the plasminogen and then leads to Ab accumulation [34] .
GLUTATHIONE REDOX IMBALANCE IN PARKINSON'S DISEASE
Parkinson's disease is a progressive neurodegenerative disease characterized by intracellular accumulation of misfolded a-synuclein (lewy bodies) and loss of dopaminergic neurons situated in the midbrain substantia nigra pars compacta. Individuals with Parkinson's disease have progressive deterioration of autonomic and motor functions, and in some cases, cognitive decline. The protein levels and activities of GPx and GST are affected in the brain of individuals with Parkinson's disease [8 & ]. GPx are a group of 1-8 enzymes. Recently, Hauser et al. [35] reported degradation and polymerization of GPx-4 following dopamine quinone exposure. This study suggests that the GPx-4 defect may increase the vulnerability of dopaminergic neurons in Parkinson's disease. Koo et al. [36] reported that a-synuclein enhanced GPX-1 activity, and GPx-1 enhanced the fibrillization of a-synuclein in vitro. Transmission electron microscopy revealed that GPX-1 was entrapped and protected by a-synuclein in a latent form, and GPX-1 activity was recovered after it was released from the matrix [36] .
There are seven classes of cytosolic GST: alpha, mu, pi, sigma, theta, omega, and zeta. Loss-of-function mutation of the PTEN-induced kinase 1 (PINK1) gene is a common cause of early-onset Parkinson's disease. Kim et al. [37, 38] reported that GST omega is regulated by the PINK1/parkin pathway, and its expression was reduced in PINK1 mutant Drosophila.
GST omega has a protective role in PINK1-associated Parkinson's disease through restoring muscle degeneration and dopaminergic neuronal loss in PINK1 mutants. Several studies have shown GST sequence polymorphisms in Parkinson's disease [8 & ]. The GST mu 1 and GST theta 1 genes are two potential candidate genes for the risk of Parkinson's disease and have been studied extensively. However, a recent meta-analysis showed that the GSTM1 polymorphism was weakly associated with the risk of Parkinson's disease in Caucasians, and that GSTT1 polymorphism is not a risk factor for Parkinson's disease [39] .
GLUTATHIONE REDOX IMBALANCE IN OTHER NEUROPSYCHIATRIC DISEASES: SCHIZOPHRENIA AND BIPOLAR DISORDER
Oxidative stress, GSH depletion, and GSH-related enzyme deficit are also extensively documented in other psychiatric diseases such as schizophrenia, bipolar disorder, and depression [40] [41] [42] . Ballesteros et al. [43] reported significantly lower GSH and higher GSSG levels in the blood of schizophrenia individuals. Dietrich-Muszalska and Kwiatkowska [44] reported that GPx activity decreased by about 67% in the platelets of individuals with schizophrenia compared with the controls.
In youth with bipolar disorder, Chitty et al. [45] reported decreased GSH levels in the hippocampus and anterior cingulated cortex, which were associated with higher alcohol and tobacco use. Rosa et al. [9] reported decreased levels of GSH and increased levels of GSSG in the plasma of bipolar disorder patients, whereas there was no change in the levels of brain-derived neurotrophic factor. The levels of GSH were associated with the age at bipolar disorder onset and not with the current mood state of the individuals.
POTENTIAL THERAPEUTIC AGENTS FOR INCREASING GLUTATHIONE LEVELS IN THE BRAIN OF INDIVIDUALS WITH GLUTATHIONE REDOX IMBALANCE
The lower cysteine levels in the brain limit de-novo GSH synthesis during oxidative stress. Therefore, increasing the levels of GSH exogenously may have potential beneficial effects for the brain disorders above. However, direct administration of GSH with the aim to increase GSH in the brain has not been successful because oral administration of GSH results in its rapid degradation in the gut, and if given intravenously, GSH is rapidly oxidized to GSSG. Instead, N-acetylcysteine (NAC) [ [49] , and Whey protein supplement [50, 51] are preferred as potential therapeutic agents to replenish GSH stores.
NAC is the N-acetyl derivative of the amino acid L-cysteine and is rapidly absorbed following oral administration, and it can cross the blood-brain barrier (BBB). After absorption, NAC is rapidly metabolized to cysteine, which is a direct precursor of GSH. NAC, as a precursor of cysteine, also regulates the glutamatergic, neurotrophic, and inflammatory pathways. Under the pro-oxidant condition of the brain, L-cysteine can get oxidized to cystine, which is the substrate of the cystineglutamate antiporter that increases glutamate release into the extracellular space in exchange for cystine. Inside the cell, cystine can be reduced to cysteine, which is used for GSH synthesis.
NAC has been in use for more than 30 years for the treatment of acetaminophen-induced hepatotoxicity. Rose et al. [52] reported that pretreatment of the autistic lymphoblastoid cell lines with NAC for 48 h could improve GSH metabolism and rescue the abnormal mitochondrial respiratory response after exposure to ROS. Ghanizadeh and Derakhshan [53] reported that the symptoms of autism were markedly improved after oral NAC administration (800 mg/day in three divided doses). In a doubleblind, randomized, placebo-controlled 12-week study of NAC in children with autism, Hardan et al. [54] have reported significant improvements in scores on Aberrant Behavior Checklist Irritability Subscale, Repetitive Behavior Scale-Revised Stereotypies Measure, and Social Responsiveness Scale. Using 7-T MRS, Holmay et al. [55] reported increased blood and brain GSH concentrations in individuals with Parkinson's disease and controls after a single NAC infusion. Unnithan et al. [56] reported that NAC protected against GSH deficit and neurotoxicity after exposure of the N2a cells to H 2 O 2 and paraquat. Reports confirmed that NAC can protect against enhanced oxidative stress in a GSH-dependent manner. Several clinical trials have been conducted using NAC as a potential therapeutic agent in various brain disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and bipolar disorder [46 && ,47 & ,48] . Most of these studies showed positive effects of NAC on clinical outcomes.
NAC can be administered orally and intravenously [57] . Its absorption occurs rapidly after oral administration of 100-600 mg NAC, although bioavailability is less than 10% [58] . Pharmacokinetics study has shown that the peak plasma concentration of NAC reached within 1-2 h after oral administration, and its half-life is 6.25 h [47 proteins. NAC is generally safe and well tolerated even at high doses. The main side-effects of NAC are nausea, vomiting, and diarrhea. Infrequently, anaphylactic reactions were observed due to the histamine release.
Liposomes encapsulated with GSH are also being developed for neuroprotection and to facilitate the delivery of GSH across the BBB [49] . These liposomes are made of lecithin and glycerol, and they get hydrolyzed to release GSH after crossing the BBB. The advantages of using these liposomes are low toxicity, low immune reaction, and high ability to cross the BBB [49] .
Ross et al. [50] have suggested that whey protein supplement (Immunocal) may be a novel therapeutic agent in neurodegenerative diseases. It acts by increasing the available GSH pool and mitigating damage by oxidative stress. Whey protein at a dose of 10-45 g/day for 2 weeks to 6 months has been shown to increase the GSH levels [51] . Whey protein is rich in sulfur-containing amino acids such as methionine and cysteine, and cysteine is the precursor of GSH. The oral administration of whey protein supplement can enhance the concentration of GSH in neurons. The whey protein is likely well tolerated when used appropriately. Its high doses can cause some side-effects such as increased bowel movements, nausea, thirst, bloating, cramps, reduced appetite, fatigue, and headache.
CONCLUSION
GSH and GSH-related enzymes are very important for maintaining the redox balance in the brain. Deficits of GSH and GSH-related enzymes are associated with many neuropsychiatric and neurodegenerative disorders, and often occur earlier than other pathological abnormalities of the disease. GSH redox imbalance appears to be more than simply a consequence of existing pathology, and it may actually be a primary cause of the disease. Moreover, GSH levels in the blood have been suggested as a biomarker of neurological disease in several studies. Agents such as NAC and whey protein supplement that can induce GSH synthesis or increase the GSH content have been shown to have beneficial effects in clinical trials and could be promising therapeutic agents for neurological disorders.
